Notice of Revision to Earnings Guidance

Details of the Revision to Earnings Guidance

By resolution of the Board of Directors announced today, the Company has revised upward its earnings guidance for the interim period of the fiscal year ending May 2027. Interim net sales are 3,500 hundred million yen, operating income is 250 hundred million yen, ordinary income is 240 hundred million yen, and interim net income is 160 hundred million yen, with interim net income per share of 39.75 yen. Compared with the previously announced guidance, net sales increased by 6.1%, operating income by 66.7%, ordinary income by 100.0%, and interim net income by 77.8%. The full-year guidance remains unchanged at this time.

Background and Points to Note Regarding the Revision

Factors behind the revision include higher-than-expected sales of imported active pharmaceutical ingredients in the pharmaceutical business, partial pull-forward of sales of the core ion-exchange resin product in the chemicals business, strong sales of high-value-added products driven by renewed activity in the semiconductor-related market, and temporary demand capture. The full-year earnings guidance is unchanged for now, and may be revised depending on future developments.